LLY - AbCellera's bamlanivimab wins EMA's positive recommendation

AbCellera ([[ABCL]] -6.1%) announced that the European Medicines Agency's ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive recommendation for bamlanivimab alone and in combination with etesevimab for the treatment of confirmed COVID-19 in certain patients aged 12 years.Bamlanivimab,  a human antibody discovered by AbCellera and developed with Eli Lilly ([[LLY]] +3.1%), has been authorized in more than 10 countries, and bamlanivimab together with etesevimab received Emergency Use Authorization ((EUA)) from the U.S. FDA on, earlier this month.The EMA reviewed Phase 2 and Phase 3 results from Eli Lilly's BLAZE-1 trial to support the CHMP opinion.Results from BLAZE-1 showed bamlanivimab alone reduced viral load and rates of symptoms and also reduced hospitalization by about 70%, and bamlanivimab and etesevimab combo reduced the risk of COVID-19 hospitalizations and death by 70% in non-hospitalized high-risk patients with mild to moderate COVID-19.The European Commission often backs the CHMP's recommendation for approval but is not

For further details see:

AbCellera's bamlanivimab wins EMA's positive recommendation